STAT+: Pharmalittle: We’re reading about Medicare price negotiations, slowing layoffs, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
Category: Pharmalot
STAT+: WTO appears close to rejecting a proposed waiver on patents for Covid diagnostics and therapies
After more than a year of deliberation, the World Trade Organization appears close to rejecting…
STAT+: Pharmalittle: We’re reading about Wegovy supplies, Biogen ditching Aduhelm, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: CMS will use outcomes-based agreements in bid to help Medicaid pay for sickle cell gene therapies
In response to concerns over multimillion-dollar price tags for new gene therapies for sickle cell…
STAT+: Pharmalittle: We’re reading about a Vertex pain pill, an abortion pill hearing, and more
Top of the morning to you. And a fine one it is. Despite gray skies,…
STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices
European antitrust regulators want you to know that fighting crime in the pharmaceutical industry pays….
STAT+: Pharmalittle: We’re reading about Medicaid and sickle cell, pharma CEOs, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Pricey sickle cell treatments raise daunting new challenges for Medicaid programs
Living with sickle cell disease has not been easy on Kourtney Cunningham. The genetic blood…
STAT+: Pharmalittle: We’re reading about Sanders jabbing Merck’s CEO, fixing drug shortages, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Generic group sues Illinois over a price-gouging law with ‘draconian regulations’
The trade group for generic drug companies in the U.S. has filed a lawsuit alleging…
.jpg)
STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: When it comes to policing pharma, the FTC says it’s on ‘an incredible winning streak’
Over the past two years, the U.S. Federal Trade Commission has attempted to crack down…
STAT+: Pharmalittle: We’re reading about Lilly’s gene therapy for hearing, Shkreli’s life-long ban, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: We’re reading about FDA warnings on CAR-T drugs, a Sanofi deal, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: We’re reading about Lilly plant problems, FDA reorganization plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: In ‘march-in’ rights, some see a tool to lower drug prices. Others see a threat to intellectual property
In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer…
STAT+: FDA scolds Novartis over a misleading TV ad for a breast cancer treatment
The U.S. Food and Drug Administration scolded Novartis for making false and misleading statements about…
STAT+: Pharmalittle: We’re reading about Sanders targeting pharma CEOs, insider trading, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Klobuchar urges drugmakers to remove patents FTC calls improper and inaccurate
Amid a push to crack down on patent abuse by the pharmaceutical industry, a key…
STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: We’re reading about a CRISPR approval, selling meds directly to patients, and more
Rise and shine, everyone. The middle of the week is upon us. Have heart, though….
STAT+: Survey: Confusion over key requirements means clinical trials aren’t registered and results aren’t reported
More than half of those responsible for registering clinical trials and reporting results fail to…
STAT+: Pharmalittle: We’re reading about Wegovy shipments, the NIH director’s plans, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market
In the latest bid to lower the cost of medicines, a new bill was introduced…
STAT+: Pharmalittle: We’re reading about GLP-1 drugs’ safety, Novartis nixing a deal, and more
And so, another working week will soon come to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about FDA’s syphillis-drug plan, India’s manufacturer-inspection demands, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Contributors to psychiatry’s bible, the DSM-5, got $14 million from industry
Amid ongoing concerns over conflicts of interest, a new study found that 60% of the…
.jpg)
STAT+: Pharmalittle: We’re reading about Sanofi’s Olympics bet, Singulair problems, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more
Rise and shine, everyone, another busy day is on the way. We can tell by…
STAT+: Florida faces ‘complicated road’ before actually importing drugs from Canada, expert says
Last week, the Food and Drug Administration granted Florida permission to import medicines from Canada,…
STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers
Several U.S. lawmakers including Sen. Bernie Sanders (I-Vt.) are investigating the prices charged by four…
STAT+: Pharmalittle: We’re reading about LillyDirect, India’s drug standards, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news
And so, another working week will soon come to a close. Not a moment too…
STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers
Several advocacy groups are blasting a Food and Drug Administration proposal to work with a…
STAT+: Pharmalittle: We’re reading about CVS dropping Humira coverage, pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news
Hello, everyone, and how are you today? We are doing fine, thank you, especially given…
STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles
Good morning, everyone, and welcome to another working week, and a new year, as well….
STAT+: 3 issues to watch in pharma in 2024
As another year comes to an end and the world seems to hit the proverbial…
STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud
And so, another working week will soon come to a close. Not a moment too…
STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer
Good morning, everyone. Damian Garde here, filling in for Ed Silverman in a week customarily…
STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace
To ring the register, a pharmaceutical company may create a patent thicket, which involves filing…
STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernathy to step down as Verily CMO
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors
Top of the morning to you. And a fine one it is. Lots of sunshine…
STAT+: Pharmalittle: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: ‘We’ve exhausted all avenues’: A small biotech may give up on its ultra-rare disease drug over frustration with FDA
Jamie Dubuque faces the future with a mixture of gratitude and trepidation. Her son, Declan,…
STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish
And so, another working week will soon draw to a close. Not a moment too…
STAT+: In response to criticism, FDA publishes new database of wayward clinical trial sponsors
In a bid toward greater transparency, the U.S. Food and Drug Administration earlier this month…
STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial
Good morning, everyone, and how are you today? We are doing just fine, thank you….